Drug Type Small molecule drug |
Synonyms |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER4 antagonists(Receptor protein-tyrosine kinase erbB-4 antagonists) + [4] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H24N6O2 |
InChIKeyCSGQVNMSRKWUSH-IAGOWNOFSA-N |
CAS Registry859853-30-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic breast cancer | Phase 2 | US | 01 Jun 2010 | |
Metastatic breast cancer | Phase 2 | MX | 01 Jun 2010 | |
Non-Small Cell Lung Cancer | Phase 2 | ES | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | TW | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | PL | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | CA | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | FR | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | AR | 01 Mar 2009 | |
Non-Small Cell Lung Cancer | Phase 2 | KR | 01 Mar 2009 |
Phase 1 | 90 | (ogtnyfiasy) = teakthzjof xcfcuggzeq (dxaoftyvlh ) View more | - | 01 May 2013 | |||
Erlotinib-naïve patients | (ogtnyfiasy) = tdfvbmtopu xcfcuggzeq (dxaoftyvlh ) View more | ||||||
Phase 1 | 30 | (qhxfrludlv) = hikzgbjoxm gnqjxjepwk (waajnxgfyr ) View more | - | 20 May 2010 | |||
Phase 1 | 65 | bfbhxqwzsl(stnatkezby) = Other grade 3–4-adverse events possibly related to BMS-690514 included angioedema rzgffwbnkz (afcxdihmfx ) View more | - | 20 May 2008 |